Drug Profile
Dalpiciclib - Jiangsu Hengrui Medicine Co
Alternative Names: AiRuiKang; Dalpiciclib Isethionate - Jiangsu Hengrui Medicine Co; SHR-6390Latest Information Update: 21 Feb 2024
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Atridia; Jiangsu Hengrui Medicine Co.; Peking University; Shanghai Jiaotong University School of Medicine; Sheng Jing Hospital; Tianjin University
- Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Cyclopentanes; Ketones; Piperidines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HER2 negative breast cancer
- Phase II Breast cancer; HER2 positive breast cancer
- Phase I/II Malignant melanoma
- Phase I Solid tumours
- No development reported Gastric cancer; Head and neck cancer
Most Recent Events
- 05 Dec 2023 Efficacy and adverse events data from a phase I/II trial in HER2-negative breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 25 Oct 2023 Jiangsu HengRui Medicine plans a phase Ib/III trial for Prostate cancer (Metastatic disease; Combination therapy) (PO, Capsule) (NCT06099990)
- 30 Jul 2023 Jiangsu HengRui Medicine Co. completes a phase-I/II clinical trials in Her2 negative Breast cancer (Combination therapy, First-line therapy, Late-stage disease, Recurrent, Metastatic disease) in China (PO) (NCT03481998)